目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T7044 | MMP Endogenous Metabolite Adrenergic Receptor Autophagy | ||
Norepinephrine (Levophed) 是β1选择性的肾上腺素能受体激动剂,EC50值为 5.37 μM。它可上调鼻咽癌肿瘤细胞中血管内皮生长因子、基质金属蛋白酶MMP-2和MMP-9的表达。 | |||
T21066 | Adrenergic Receptor | ||
Norepinephrine bitartrate salt 是一种肾上腺素能神经递质。 | |||
T1064 | Endogenous Metabolite Adrenergic Receptor Autophagy | ||
Norepinephrine bitartrate monohydrate (Levophed) 是一种β1-选择性的肾上腺素能受体激动剂,EC50为 5.37 μM。 | |||
T13655 | Adrenergic Receptor | ||
DL-Norepinephrine hydrochloride (DL-lysine) 是一种靶向α1 adrenoceptor 和β1 adrenoceptor 的神经递质,可降低心内膜下氧分压。它是一种模拟内源性去甲肾上腺素的拟交感神经作用的合成苯乙胺。 | |||
T60245 | |||
Norepinephrine hydrochloride (Levarterenol hydrochloride) 是一种β1选择性的肾上腺素受体激动剂,EC50值为 5.37 μM。 | |||
T20173 | |||
Norepinephrine bitartrate is a precursor of epinephrine. Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers and of the diffuse projection system in the brain arising from the locus ceruleus. | |||
T8708 | Serotonin Transporter | ||
Paroxetine 是选择性血清素再摄取抑制剂,是苯基哌啶的衍生物。 它对于甲肾上腺素摄取抑制功能较弱,但比该位点其他SSRIs 更有效。 | |||
T0300 | MAO Monoamine Oxidase | ||
Pargyline (Pargylamine) 是不可逆的单胺氧化酶抑制剂,对MAO-A 和MAO-B 的Ki 分别为 13 μM 和 0.5 μM,具有降压和抗癌作用。 | |||
T22453 | Serotonin Transporter | ||
Venlafaxine (Wy 45030) 是一种口服有效的 5-羟色胺 (5-HT)/去甲肾上腺素 (NE) 重摄取的双重抑制剂,具有抗抑郁活性。 | |||
T1997 | Neuropeptide Y Receptor | ||
JNJ-31020028是神经肽Y2受体选择性可脑渗透抑制剂,对人Y2和鼠源Y2受体pIC50值分别为8.07和8.22,其神经肽 Y2 受体的选择性比人 Y1/Y4/Y5 受体高 100 倍。 |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPY-03852 | Dopamine beta-Hydroxylase Protein, Human, Recombinant (His) | Human | HEK293 | ||
DBH is a 29 kDa copper-containing oxygenase. It can be detected in noradrenergic nerve terminals of the central and peripheral nervous systems, and is also expressed in chromaffin cells of the adrenal medulla. DBH contains our identical subunits, and its activity requires ascorbate as a cofactor. It functions in in the synthesis of small-molecule neurotransmitters that is membrane-bound, making norepinephrine the only transmitter synthesized inside vesicles. DBH has been shown to be associated with decision making and addictive behaviors such as alcohol and smoking, attention deficit hyperactivity disorder, and also with neurological diseases such as Schizophrenia and Alzheimer's.
|
|||||
TMPY-02948 | SULT1A3 Protein, Human, Recombinant (His) | Human | E. coli | ||
SULT1A3 belongs to the sulfotransferase 1 family. Sulfotransferase enzymes catalyze the sulfate conjugation of many hormones, neurotransmitters, drugs, and xenobiotic compounds. They are different in their tissue distributions and substrate specificities while their gene structure (number and length of exons) is similar. SULT1A3 gene encodes a phenol sulfotransferase with thermolabile enzyme activity. Four sulfotransferase genes are located on the p arm of chromosome 16; this gene and SULT1A4 arose from a segmental duplication. It is the most centromeric of the four sulfotransferase genes. Exons of this gene overlap with exons of a gene that encodes a protein containing GIY-YIG domains (GIYD1). SULT1A3 is expressed in liver, colon, kidney, lung, brain, spleen, small intestine, placenta and leukocyte. SULT1A3 is a sulfotransferase that utilizes 3'-phospho-5'-adenylyl sulfate (PAPS) as sulfonate donor to catalyze the sulfate conjugation of phenolic monoamines (neurotransmitters such as dopamine, norepinephrine and serotonin) and phenolic and catechol drugs.
|